0001415889-24-019829.txt : 20240719
0001415889-24-019829.hdr.sgml : 20240719
20240719203544
ACCESSION NUMBER: 0001415889-24-019829
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240718
FILED AS OF DATE: 20240719
DATE AS OF CHANGE: 20240719
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lizzul Paul F.
CENTRAL INDEX KEY: 0001711462
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 241129064
MAIL ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD
STREET 2: SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO, INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYSBIO INC
DATE OF NAME CHANGE: 20080828
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
form4-07202024_120740.xml
X0508
4
2024-07-18
0001370053
ANAPTYSBIO, INC
ANAB
0001711462
Lizzul Paul F.
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
CA
92121
false
true
false
false
Chief Medical Officer
1
Common Stock
2024-07-18
4
M
0
1500
18.50
A
13118
D
Common Stock
2024-07-18
4
S
0
1500
35
D
11618
D
Common
18.50
2024-07-18
4
M
0
1500
0
D
2030-07-30
Common
1500
88500
D
Reflects the acquisition of 1,500 shares acquired under the Company's ESPP.
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023.
The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
In addition to the remaining options to purchase 88,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms.
/s/ Eric Loumeau, Attorney-in-Fact
2024-07-19